Supriya Lifescience

688.60
-18.00
(-2.55%)
Market Cap
5,542.05 Cr
EPS
14.80
PE Ratio
32.60
Dividend Yield
0.11 %
Industry
Healthcare
52 Week High
842.00
52 Week Low
330.00
PB Ratio
6.28
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from1 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,787.40
#1 4,28,857.13
36.71
#1 49,887.20
12.06
#1 9,648
13.77
59.27
6,012.50
1,59,612.98
79.83
8,184.00
0.89
1,600
#1 64.53
57.99
1,525.90
1,23,233.96
25.11
26,520.70
14.17
4,155
47.38
57.43
3,238.90
1,09,619.09
60.42
10,785.70
11.59
1,656
13.54
52.37
2,557.50
1,05,516.96
52.60
10,615.60
19.57
1,942
-16.38
59.98
1,174.80
98,031.82
#1 18.66
28,905.40
12.36
5,578
1.69
54.12
2,019.60
92,203.01
33.50
20,141.50
#1 19.94
1,936
38.82
50.28
859.65
86,500.90
19.53
19,831.50
13.82
3,831
29.92
46.44
1,220.10
70,863.61
20.72
29,559.20
17.55
3,169
-10.04
58.85
29,705.00
63,121.05
47.82
6,097.20
10.80
1,201
16.01
45.94
Growth Rate
Revenue Growth
23.51 %
Net Income Growth
32.48 %
Cash Flow Change
78.13 %
ROE
13.70 %
ROCE
13.74 %
EBITDA Margin (Avg.)
7.41 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
Revenue
140
172
191
222
286
323
396
538
470
581
680
Expenses
121
150
166
191
213
213
218
316
332
397
422
EBITDA
20
22
25
31
73
110
178
222
138
184
258
Operating Profit %
12 %
12 %
9 %
10 %
23 %
32 %
44 %
40 %
28 %
30 %
37 %
Depreciation
3
4
5
5
5
6
7
10
12
16
18
Interest
7
10
12
11
10
7
4
4
3
2
2
Profit Before Tax
10
8
8
15
57
96
167
207
124
166
238
Tax
2
2
2
6
18
23
44
55
34
47
53
Net Profit
8
6
6
9
39
73
124
152
90
119
175
EPS in ₹
16.82
3.89
3.87
1.19
5.39
10.02
16.89
18.86
11.16
14.80
21.70

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
176
231
241
245
253
336
446
735
820
921
Fixed Assets
61
76
89
91
85
99
100
190
262
310
Current Assets
103
129
115
120
133
196
266
498
465
398
Capital Work in Progress
11
25
36
34
35
40
79
43
68
149
Investments
0
0
0
0
0
0
0
0
25
64
Other Assets
104
131
117
120
133
197
267
502
466
399
Total Liabilities
176
231
241
245
253
336
446
735
820
921
Current Liabilities
115
150
144
146
135
155
146
100
96
77
Non Current Liabilities
23
39
51
45
24
32
31
19
25
29
Total Equity
37
42
46
55
94
149
269
616
700
815
Reserve & Surplus
33
26
31
40
79
134
254
600
683
799
Share Capital
5
15
15
15
15
15
15
16
16
16

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
1
2
-2
3
4
62
15
139
-70
-83
Investing Activities
-23
-33
-27
-5
5
-25
-47
-60
-124
-174
Operating Activities
-6
14
27
28
49
117
76
49
64
113
Financing Activities
30
21
-2
-20
-50
-29
-15
150
-10
-22

Share Holding

% Holding
May 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
99.98 %
68.24 %
68.24 %
68.24 %
68.24 %
68.24 %
68.28 %
68.30 %
68.30 %
68.30 %
68.30 %
68.30 %
68.30 %
68.30 %
68.30 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
5.34 %
0.00 %
5.36 %
4.95 %
6.03 %
6.52 %
7.19 %
DIIs
0.00 %
5.20 %
4.72 %
7.27 %
6.23 %
7.89 %
7.65 %
7.55 %
7.17 %
3.85 %
5.30 %
5.48 %
5.45 %
4.92 %
4.26 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
8.25 %
12.73 %
12.52 %
13.40 %
15.07 %
15.54 %
15.39 %
16.10 %
17.50 %
17.06 %
17.19 %
0.00 %
16.28 %
16.40 %
Others
0.02 %
18.30 %
14.31 %
11.97 %
12.13 %
8.80 %
8.53 %
8.76 %
3.09 %
10.35 %
3.98 %
4.08 %
20.23 %
3.98 %
3.85 %
No of Share Holders
7
50,506
82,578
86,853
94,594
96,998
95,605
93,478
92,991
95,929
87,980
89,621
85,328
89,394
91,051

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.54 0.6 0.6 0.8 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.11 0.32 0.18 0.11 0.00

Corporate Action

Announcements

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report2 days ago
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 01, 2025
Closure of Trading WindowMar 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 25, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotMar 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 17, 2025
Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 10, 2025
Appointment of Company Secretary and Compliance OfficerMar 10, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held To Consider Appointment Of Company Secretary And Compliance Officer Of The Company.Mar 10, 2025
Board Meeting Intimation for Appointment Of Company Secretary And Compliance Officer Of The CompanyMar 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 18, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 01, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 31, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 27, 2025
Audio Recording Of Earnings CallJan 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Jan 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 25, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 24, 2025
Integrated Filing (Financial)Jan 24, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJan 24, 2025
Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 24, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateJan 24, 2025
Unaudited Financial Results For The Quarter And Nine Month Ended December 31 2024Jan 24, 2025
Board Meeting Outcome for Outcome Of Board Meeting In Accordance With SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 17, 2025
Board Meeting Intimation for Regulation 29(1) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 02, 2025
Intimation Of Change In Name Of RTAJan 02, 2025
Reply To Clarification On News Item Appearing In "Media/PublicationJan 01, 2025
Clarification sought from Supriya Lifescience LtdJan 01, 2025
Closure of Trading WindowDec 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 30, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 17, 2024

Technical Indicators

RSI(14)
Neutral
46.40
ATR(14)
Less Volatile
44.28
STOCH(9,6)
Neutral
50.20
STOCH RSI(14)
Oversold
14.14
MACD(12,26)
Bearish
-5.21
ADX(14)
Weak Trend
17.88
UO(9)
Bullish
29.71
ROC(12)
Downtrend And Accelerating
-2.97
WillR(14)
Neutral
-64.64